Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

David Seiter

Nurse Practitioner, Family Farmington, NM Nurse Practitioner

NPI 1891190567 CMS profile 10779494

5512 E Main St Ste A, Farmington, NM 87402

Open in the dashboard

General payments

$194,224

1,298 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Seiter of Farmington, NM is reported in the CMS Open Payments database as having received $194,224 across 1,298 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $144,299 483
2024 General $26,396 268
2023 General $17,434 244
2022 General $3,282 152
2021 General $2,813 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Seiter
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to David Seiter were reported at $144,299. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year David Seiter Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,813 $124 $35–$379 $132
2022 $3,282 $141 $44–$430 $149
2023 $17,434 $154 $49–$476 $160
2024 $26,396 $165 $51–$504 $164
2025 $144,299 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $46,044 135 payments
  2. Galderma Laboratories, L.P. $40,731 153 payments
  3. UCB, Inc. $39,396 125 payments
  4. Genzyme Corporation $37,466 80 payments
  5. Incyte Corporation $6,768 55 payments
  6. Arcutis Biotherapeutics, Inc. $6,167 35 payments
  7. AbbVie, Inc. $4,345 187 payments
  8. LEO Pharma Inc. $2,073 40 payments
  9. Janssen Biotech, Inc. $1,936 67 payments
  10. Sun Pharmaceutical Industries Inc. $1,567 71 payments
  11. Other $7,732 350 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $128,277 72 payments
  2. Food and Beverage $30,231 1,097 payments
  3. Consulting Fee $18,573 11 payments
  4. Travel and Lodging $16,608 102 payments
  5. Education $536 16 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $38,606 97 payments
  2. DUPIXENT Immunology And Inflammation $33,484 71 payments
  3. DUPIXENT Immunology $32,533 86 payments
  4. NEMLUVIO $32,044 86 payments
  5. DUPIXENT Inflammation And Immunology $12,655 57 payments
  6. SKYRIZI $1,638 66 payments
  7. TREMFYA $1,628 40 payments
  8. RINVOQ $1,411 65 payments
  9. OPZELURA $1,121 41 payments
  10. ADBRY $1,058 35 payments
  11. Other $15,460 806 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,008

Median for Nurse Practitioner: 389

Drug cost

$566,487

Median for Nurse Practitioner: $21,885

Branded share of claims

14.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 72 $311,839
Cosentyx Unoready Pen Secukinumab Brand 15 $151,864
Adbry Tralokinumab-Ldrm Brand 20 $74,782
Tacrolimus Generic 54 $7,499
Clobetasol Propionate Generic 125 $4,805
Fluorouracil Generic 54 $3,846
Ketoconazole Generic 93 $1,806
Triamcinolone Acetonide Generic 129 $1,451
Valacyclovir Valacyclovir Hcl Brand 25 $1,003
Clindamycin Phosphate Generic 25 $997

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$146,320

Of which drugs: $1,476

Medicare patients

655

Average age 74

Services billed

4,544

228 women, 427 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 48%
Ischemic heart disease 25%
Diabetes 23%
Chronic kidney disease 23%
Atrial fibrillation 15%
Cancer 14%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 37 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$14,329 72 —
TREMFYA
$515 — —
Bimzelx
$380 — —
SKYRIZI
$330 — —
OPZELURA
$325 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,298 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record